181 related articles for article (PubMed ID: 15535433)
1. Aryplase (Biomarin).
Yogalingam G
Curr Opin Investig Drugs; 2004 Oct; 5(10):1111-20. PubMed ID: 15535433
[TBL] [Abstract][Full Text] [Related]
2. Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase.
Harmatz P; Ketteridge D; Giugliani R; Guffon N; Teles EL; Miranda MC; Yu ZF; Swiedler SJ; Hopwood JJ;
Pediatrics; 2005 Jun; 115(6):e681-9. PubMed ID: 15930196
[TBL] [Abstract][Full Text] [Related]
3. Galsulfase: arylsulfatase B, BM 102, recombinant human arylsulfatase B, recombinant human N-acetylgalactosamine-4-sulfatase, rhASB.
Drugs R D; 2005; 6(5):312-5. PubMed ID: 16128602
[TBL] [Abstract][Full Text] [Related]
4. Galsulfase.
Hopwood JJ; Bate G; Kirkpatrick P
Nat Rev Drug Discov; 2006 Feb; 5(2):101-2. PubMed ID: 16521329
[No Abstract] [Full Text] [Related]
5. Molecular markers for the follow-up of enzyme-replacement therapy in mucopolysaccharidosis type VI disease.
Di Natale P; Villani GR; Parini R; Scarpa M; Parenti G; Pontarelli G; Grosso M; Sersale G; Tomanin R; Sibilio M; Barone R; Fiumara A
Biotechnol Appl Biochem; 2008 Mar; 49(Pt 3):219-23. PubMed ID: 17672828
[TBL] [Abstract][Full Text] [Related]
6. Enzyme replacement therapy with galsulfase for mucopolysaccharidosis VI: clinical facts and figures.
Harmatz P
Turk J Pediatr; 2010; 52(5):443-9. PubMed ID: 21434527
[TBL] [Abstract][Full Text] [Related]
7. Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study.
Harmatz P; Giugliani R; Schwartz I; Guffon N; Teles EL; Miranda MC; Wraith JE; Beck M; Arash L; Scarpa M; Yu ZF; Wittes J; Berger KI; Newman MS; Lowe AM; Kakkis E; Swiedler SJ;
J Pediatr; 2006 Apr; 148(4):533-539. PubMed ID: 16647419
[TBL] [Abstract][Full Text] [Related]
8. Successful management of difficult infusion-associated reactions in a young patient with mucopolysaccharidosis type VI receiving recombinant human arylsulfatase B (galsulfase [Naglazyme]).
Kim KH; Decker C; Burton BK
Pediatrics; 2008 Mar; 121(3):e714-7. PubMed ID: 18250117
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamics, pharmacokinetics and biodistribution of recombinant human N-acetylgalactosamine 4-sulfatase after 6months of therapy in cats using different IV infusion durations.
Ruane T; Haskins M; Cheng A; Wang P; Aguirre G; Knox VW; Qi Y; Tompkins T; O'Neill CA
Mol Genet Metab; 2016 Feb; 117(2):157-63. PubMed ID: 26776148
[TBL] [Abstract][Full Text] [Related]
10. Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome).
Harmatz P; Whitley CB; Waber L; Pais R; Steiner R; Plecko B; Kaplan P; Simon J; Butensky E; Hopwood JJ
J Pediatr; 2004 May; 144(5):574-80. PubMed ID: 15126989
[TBL] [Abstract][Full Text] [Related]
11. Intrathecal recombinant human 4-sulfatase reduces accumulation of glycosaminoglycans in dura of mucopolysaccharidosis VI cats.
Auclair D; Finnie J; Walkley SU; White J; Nielsen T; Fuller M; Cheng A; O'Neill CA; Hopwood JJ
Pediatr Res; 2012 Jan; 71(1):39-45. PubMed ID: 22289849
[TBL] [Abstract][Full Text] [Related]
12. Abnormal granulation of blood granulocytes in mucopolysaccharidosis VI-a case report.
Krishnagiri C; Ajanahalli RR; Kashyap S; Anegundi R; Boranaik L
Ann Diagn Pathol; 2013 Feb; 17(1):137-9. PubMed ID: 22056033
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic profile of recombinant human N-acetylgalactosamine 4-sulphatase enzyme replacement therapy in patients with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): a phase I/II study.
Harmatz P; Kramer WG; Hopwood JJ; Simon J; Butensky E; Swiedler SJ;
Acta Paediatr Suppl; 2005 Mar; 94(447):61-8; discussion 57. PubMed ID: 15895715
[TBL] [Abstract][Full Text] [Related]
14. Immune response to enzyme replacement therapy: 4-sulfatase epitope reactivity of plasma antibodies from MPS VI cats.
Turner CT; Hopwood JJ; Bond CS; Brooks DA
Mol Genet Metab; 1999 Jul; 67(3):194-205. PubMed ID: 10381327
[TBL] [Abstract][Full Text] [Related]
15. Monitoring dose response of enzyme replacement therapy in feline mucopolysaccharidosis type VI by tandem mass spectrometry.
Crawley A; Ramsay SL; Byers S; Hopwood J; Meikle PJ
Pediatr Res; 2004 Apr; 55(4):585-91. PubMed ID: 14711884
[TBL] [Abstract][Full Text] [Related]
16. [Maroteaux-Lamy syndrome].
Matsushita Y; Kuroiwa Y
Ryoikibetsu Shokogun Shirizu; 2000; (29 Pt 4):468-9. PubMed ID: 11031996
[No Abstract] [Full Text] [Related]
17. Long-term intra-articular administration of recombinant human N-acetylgalactosamine-4-sulfatase in feline mucopolysaccharidosis VI.
Auclair D; Hopwood JJ; Lemontt JF; Chen L; Byers S
Mol Genet Metab; 2007 Aug; 91(4):352-61. PubMed ID: 17544310
[TBL] [Abstract][Full Text] [Related]
18. Mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome): a Y210C mutation causes either altered protein handling or altered protein function of N-acetylgalactosamine 4-sulfatase at multiple points in the vacuolar network.
Bradford TM; Litjens T; Parkinson EJ; Hopwood JJ; Brooks DA
Biochemistry; 2002 Apr; 41(15):4962-71. PubMed ID: 11939792
[TBL] [Abstract][Full Text] [Related]
19. Up to five years experience with 11 mucopolysaccharidosis type VI patients.
Brands MM; Oussoren E; Ruijter GJ; Vollebregt AA; van den Hout HM; Joosten KF; Hop WC; Plug I; van der Ploeg AT
Mol Genet Metab; 2013 May; 109(1):70-6. PubMed ID: 23523338
[TBL] [Abstract][Full Text] [Related]
20. An index case for the attenuated end of the mucopolysaccharidosis type VI clinical spectrum.
Brooks DA; Gibson GJ; Karageorgos L; Hein LK; Robertson EF; Hopwood JJ
Mol Genet Metab; 2005 Jul; 85(3):236-8. PubMed ID: 15979036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
